Lorenzo Piemonti

Un grazie a Radio 24 per l’invito a Il Cowboy e lo Stivale. Stimolante il confronto con Giuseppe Remuzzi e Andrew Spannaus su sanità, obesità e diabete: come abitudini, ambiente e politiche sanitarie plasmano la nostra salute.
www.radio24.ilsole24ore.com/programmi/Il...
#Diabete #Obesità #Radio24

Long-term follow-up of pancreatic islet transplantation in a patient with Wolfram syndrome: a case report - Acta Diabetologica Acta Diabetologica -

🧬 New case report in Acta Diabetologica: 10-year follow-up of islet transplantation in a patient with Wolfram syndrome.
Non-autoimmune, insulinopenic diabetes — still responsive to beta-cell replacement.
Rethinking eligibility.
🔗 doi.org/10.1007/s005...
#Diabetes #IsletTx

“Pole pole” — I learned it climbing Kilimanjaro: slow, steady, with respect.
Now it’s the spirit of our new @AmJTransplant commentary on cautiously exploring IAT in IPMN patients.
Science moves best when it listens.
👉 doi.org/10.1016/j.aj...
#IAT #IPMN #PolePole

Frontiers Publishing Partnerships | Comparative Analysis of Islet Auto-Transplantation Outcome Classification Systems: Evaluating Concordance, Feasibility, and a Data-Driven Approach A standardized approach to assessing islet autotransplantation outcomes is crucial for evaluating graft function and guiding clinical decisions. This study c...

How should we assess graft function after islet autotransplantation?
A study from @SanRaffaeleMI compares 6 outcome classification systems—including a data-driven model that better captures intermediate outcomes.
www.frontierspartnerships.org/journals/tra...

Future Directions and Clinical Trial Considerations for Novel Islet β-Cell Replacement Therapies for Type 1 Diabetes Type 1 diabetes results from the immune-mediated loss of insulin-producing pancreatic islet β-cells, rendering those affected dependent on exogenous insuli

Can β-cell replacement therapies for type 1 diabetes move beyond being a last resort?
In this new Diabetes article, we explore what’s possible, what’s needed, and what questions remain.
📄 doi.org/10.2337/dbi2...
#T1D #BetaCell #DiabetesResearch

#ESPEESE2025 has just wrapped up in Copenhagen!
We joined the Meet the Expert session on #Type1Diabetes therapies as guests from the DRI @SanRaffaeleMI.
The real challenge? Endocrine care that follows the patient across their whole life.
Easy to say… hard to do… but not impossible.
#SanRaffaeleMI

We’re excited to share our latest work published in the American Journal of Transplantation: Islet Autotransplantation in Focal Intraductal Papillary Mucinous Neoplasms: Evaluating Feasibility, Safety, and Metabolic Outcomes in Pancreatic Resection kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F...

April 11, 2025 – National Day for Organ Donation and Transplantation.
The breath becomes silence, but it doesn’t end.
Time just changes its body.
#OrganDonation #DonateLife #April11

www.facebook.com/share/v/1HSJ...

Liraglutide treatment reverses unconventional cellular defects in induced pluripotent stem cell-derived β cells harboring a partially functional WFS1 variant Wolfram Syndrome 1 (WS1) is a rare genetic disorder caused by WFS1 variants that disrupt Wolframin, an endoplasmic reticulum-associated protein essential f

We’ve been exploring the potential of GLP-1 receptor agonists for treating Wolfram Syndrome, a rare form of diabetes.
#WolframSyndrome #GLP1 diabetesjournals.org/diabetes/art...

Frontiers Publishing Partnerships | The Last Mile in Beta-Cell Replacement Therapy for Type 1 Diabetes: Time to Grow Up Beta cell replacement therapy for type 1 diabetes (T1D) is undergoing a transformative shift, driven by advances in stem cell biology, gene editing, and tiss...

Just published www.frontierspartnerships.org/journals/tra...

Bringing new therapy to patients needs strong clinical trials and regulatory alignment. Europe is updating GCP guidelines (ICH E6(R3)) to boost efficiency while ensuring safety and transparency
💡 Why does it matter?
To deliver innovative therapies faster.
#CellTherapies #Diabetes #GCP #ACTEUworkshop

Long-term outcomes of pancreatic islet transplantation alone in type 1 diabetes: a 20-year single-centre study in Italy This analysis of a large islet transplantation alone cohort provides valuable insights into factors influencing outcomes and highlights potential risks, supporting informed clinical decision making an...

A long story about our activity just published

Long-term outcomes of pancreatic islet transplantation alone in type 1 diabetes: a 20-year single-centre study in Italy - The Lancet Diabetes & Endocrinology www.thelancet.com/journals/lan...